ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE

被引：0
|
作者：
Osterman, Mark T.
Gordon, Ilyssa O.
Davis, Elisabeth M.
Ciorba, Matthew A.
Glover, Sarah C.
Abraham, Bincy P.
Khan, Freeha
Shen, Bo
Yee, Eric
Allard, Felicia
Liu, Julia J.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 03期
关键词：
D O I：
10.1053/j.gastro.2019.01.148
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P087
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [41] Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease
    Holmer, Ariela K.
    Battat, Robert
    Dulai, Parambir S.
    Vande Casteele, Niels
    Nguyen, Nghia
    Jain, Anjali
    Miralles, Ara
    Neill, Jennifer
    Le, Helen
    Singh, Siddharth
    Rivera-Nieves, Jesus
    Sandborn, William J.
    Boland, Brigid S.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [42] Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab
    Petkau, Jill M. V.
    Eksteen, Bertus
    BIOLOGICS-TARGETS & THERAPY, 2016, 10 : 33 - 52
  • [43] Crohn's Disease Is Associated With Activation of Circulating Innate Lymphoid Cells
    Mazzurana, Luca
    Bonfiglio, Ferdinando
    Forkel, Marianne
    D'Amato, Mauro
    Halfvarson, Jonas
    Mjosberg, Jenny
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (07) : 1128 - 1138
  • [44] BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN'S DISEASE
    Alexdottir, Marta Sorokina
    Bourgonje, Arno R.
    Karsdal, Morten Asser
    Bay-Jensen, Anne-Christine
    Pehrsson, Martin
    Loveikyte, Roberta
    Van Dullemen, Hendrik M.
    Visschedijk, Marijn C.
    Festen, Eleonora A.
    Weersma, Rinse K.
    Faber, Klaas Nico
    Dijkstra, Gerard
    Mortensen, Joachim Hog
    GASTROENTEROLOGY, 2022, 162 (07) : S802 - S803
  • [45] Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease
    Dulai, Parambir S.
    Boland, Brigid S.
    Singh, Siddharth
    Chaudrey, Khadija
    Koliani-Pace, Jenna L.
    Kochhar, Gursimran
    Parikh, Malav P.
    Shmidt, Eugenia
    Hartke, Justin
    Chilukuri, Prianka
    Meserve, Joseph
    Whitehead, Diana
    Hirten, Robert
    Winters, Adam C.
    Katta, Leah G.
    Peerani, Farhad
    Narula, Neeraj
    Sultan, Keith
    Swaminath, Arun
    Bohm, Matthew
    Lukin, Dana
    Hudesman, David
    Chang, John T.
    Rivera-Nieves, Jesus
    Jairath, Vipul
    Zou, G. Y.
    Feagan, Brian G.
    Shen, Bo
    Siegel, Corey A.
    Loftus, Edward V., Jr.
    Kane, Sunanda
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Sandborn, William J.
    Lasch, Karen
    Cao, Charlie
    GASTROENTEROLOGY, 2018, 155 (03) : 687 - +
  • [46] Risk factors for clinical phenotypes of Crohn's disease of the ileal pouch
    Shen, Bo
    Fazio, Victor W.
    Remzi, Feza H.
    Bennett, Ana E.
    Brzezinski, Aaron
    Lopez, Rocio
    Oikonomou, Ioannis
    Sherman, Kerry K.
    Lashner, Bret
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (12): : 2760 - 2768
  • [47] DNA methylation profiles accurately predict vedolizumab response and remain stable during induction and maintenance treatment in Crohn's disease
    Joustra, V.
    Hageman, I.
    Yim, A. Li
    Gecse, K.
    Lowenberg, M.
    te Velde, A.
    Satsangi, J.
    de Jonge, W.
    Henneman, P.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S639 - S639
  • [48] Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn's disease
    Alexdottir, M. Sorokina
    Bourgonje, A. R.
    Karsdal, M. A.
    Bay-Jensen, A. C.
    Pehrsson, M.
    Loveikyte, R.
    van Dullemen, H. M.
    Visschedijk, M. C.
    Festen, E. A. M.
    Weersma, R. K.
    Faber, K. N.
    Dijkstra, G.
    Joachim, M. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I468 - I469
  • [49] Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn's disease
    Alexdottir, M. Sorokina
    Bourgonje, A. R.
    Karsdal, M. A.
    Bay-Jensen, A. C.
    Pehrsson, M.
    Loveikyte, R.
    van Dullemen, H. M.
    Visschedijk, M. C.
    Festen, E. A. M.
    Weersma, R. K.
    Faber, K. N.
    Dijkstra, G.
    Joachim, M. H.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I468 - I469
  • [50] APPLICATION OF THE CLINICAL DECISION SUPPORT TOOL TO PREDICT TREATMENT OUTCOMES IN CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB SUBCUTANEOUS FORMULATION
    Dulai, Parambir S.
    Lindner, Dirk
    Agboton, Christian
    Alric, Hadrien
    Bamias, Giorgos
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2023, 164 (06) : S307 - S308
12345